Simcere Pharmaceutical Group (FRA:S2P) Growth Rank: 10 (As of Sep. 08, 2026) — 11% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:S2P Simcere Pharmaceutical Group Ltd FRA:S2P
95 GF Score
Price €1.25
GF Value €1.21
Valuation Fairly Valued
View Full Analysis

What is Simcere Pharmaceutical Group Growth Rank?

Simcere Pharmaceutical Group FRA:S2P -6.72% 95 Growth Rank is 10 as of Sep. 08, 2026, which is 11% above its 10-year median of 9.00. GuruFocus rates FRA:S2P with a GF Score™ of 95/100 and a GF Value™ of €1.21 (Fairly Valued).

Simcere Pharmaceutical Group has the Growth Rank of 10.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Simcere Pharmaceutical Group Growth Rank Related Terms

FRA:S2P vs ZTS: Growth Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Simcere Pharmaceutical Group's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Simcere Pharmaceutical Group Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Simcere Pharmaceutical Group's Growth Rank distribution charts can be found below:

* The bar in red indicates where Simcere Pharmaceutical Group's Growth Rank falls into.


FRA:S2P
95GF Score
Simcere Pharmaceutical Group Ltd FRA:S2P
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 10 mean?
Simcere Pharmaceutical Group (FRA:S2P) has a Growth Rank of 10 as of Sep. 08, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Simcere Pharmaceutical Group and its competitors. This is 11% above median its historical median of 9.00. Over the past decade, Simcere Pharmaceutical Group's Growth Rank has ranged from 8.00 to 10.00.
Is Simcere Pharmaceutical Group's Growth Rank too high?
Simcere Pharmaceutical Group's current Growth Rank of 10 is 11% above median its 10-year median of 9.00. Over the past 10 years, this metric has ranged from a low of 8.00 to a high of 10.00. Overall, Simcere Pharmaceutical Group has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Simcere Pharmaceutical Group's Growth Rank compare to ZTS?
Simcere Pharmaceutical Group's Growth Rank of 10 can be compared against companies in the Drug Manufacturers industry. Historically, Simcere Pharmaceutical Group's own Growth Rank has ranged from 8.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Simcere Pharmaceutical Group and its competitors. Simcere Pharmaceutical Group's current Growth Rank is 10, which is 11% above median its own 10-year median of 9.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simcere Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group (FRA:S2P) is currently considered Fairly Valued. The stock's GF Value™ is €1.21, compared to a current price of €1.25 — trading 3.3% above its estimated fair value. The current Growth Rank is 10, which is 11% above median its 10-year median of 9.00. Simcere Pharmaceutical Group's overall GF Score™ is 95/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Simcere Pharmaceutical Group (FRA:S2P), the current Growth Rank is 10 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Simcere Pharmaceutical Group (FRA:S2P) Overvalued in 2026?

Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued. The current stock price of €1.25 is trading 3.3% above its estimated GF Value™ of €1.21. GuruFocus considers Simcere Pharmaceutical Group to be Fairly Valued.

Key valuation signals for FRA:S2P:

  • Growth Rank: 10 (11% above median its 10-year median of 9.00)
  • GF Value™: €1.21 vs. price of €1.25 (3.3% above fair value)
  • GF Score™: 95/100

No single metric tells the full story. See the FRA:S2P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Simcere Pharmaceutical Group Business Description

Other Exchanges 02096:Hong KongS2P:Germany
Address No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu Province, Nanjing, CHN, 210042
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
95GF Score

Get the complete analysis for FRA:S2P

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.25
Price
€1.21
GF Value